Keyword Suggestion
Domain Informations
| Domain Provider | Number Of Domains |
|---|---|
| godaddy.com | 286730 |
| namecheap.com | 101387 |
| networksolutions.com | 69118 |
| tucows.com | 52617 |
| publicdomainregistry.com | 39120 |
| whois.godaddy.com | 32793 |
| enomdomains.com | 23825 |
| namesilo.com | 21429 |
| domains.google.com | 21384 |
| cloudflare.com | 20573 |
| gmo.jp | 18110 |
| name.com | 17601 |
| fastdomain.com | 14708 |
| register.com | 13495 |
| net.cn | 12481 |
| ionos.com | 12416 |
| ovh.com | 12416 |
| gandi.net | 12305 |
| registrar.amazon.com | 12111 |
Host Informations
- IP address: 185.217.43.20
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
Site Inspections
Port Scanner (IP: 185.217.43.20)
Spam Check (IP: 185.217.43.20)
Recent Searched Sites
› Jardineriaon.com (14 seconds ago) / ES
› Chikuma-nk.com (29 seconds ago) / US
› Ekosport.fr (29 seconds ago) / US
› Bloggingkiss.com (45 seconds ago) / CL
› Fida.cz (47 seconds ago) / CZ
› Javlovers.club (28 seconds ago) / AU
› Tradeford.com (3 seconds ago) / US
› Biosimilars.stada (0 seconds ago) / GB
› Fabflair.shop (18 seconds ago) / US
› Bikebargains.co.uk (3 seconds ago) / GB
› Psnews.com.au (1 seconds ago) / US
› Catalog.mgccc.edu (12 seconds ago) / US
› Silutesskelbimai.lt (10 seconds ago) / LT
› Apimio.com (1 mins ago) /
› Films1080.best (34 seconds ago) / US
› Chakatsu.com (12 seconds ago) / US
› Zadowolenie.pl (1 mins ago) / PL
› Derkleinekaufmann.de (5 seconds ago) / DE
› Orama.com.br (49 seconds ago) / US
› Swimvietnamse.com (1 mins ago) / CA
Websites Listing
We found Websites Listing below when search with biosimilars.stada on Search Engine
What are biosimilars? | Biosimilars
STADA was one of the first companies to launch biosimilars in 2008. We already have a portfolio of more biosimilars for a range of indications. These include therapeutic areas like nephrology, osteoporosis, and oncology. STADA will continuously expand its portfolio.
Biosimilars.stadaBiosimilars | Biosimilars
Besides OTC and Generics, we focus on specialties like biosimilars, in therapeutic areas of nephrology, oncology, diabetes, and ophthalmology. 2006. The introduction of the first biosimilar in clinical use > 30 . Biosimilars approved for use in the EU to date as of March 2019* 20 to 25%. Savings compared to reference products* 2006. The introduction of the first biosimilar in …
Biosimilars.stadaOur mission | Biosimilars
As STADA, we fundamentally care for people’s health as a trusted partner. In pursuit of this purpose, we are committed to further accelerating the successful trajectory of our company. “In the last decade, our biosimilars business has grown significantly, driven by our continued dedication. We acknowledge that the foundation of our biosimilars has been laid by others, …
Biosimilars.stadaBiosimilar Switching: The Evidence on Its Utility and ...
2020-05-11 · Recently, Big Molecule Watch provided an update on the team of Xbrane and STADA. The partners have apparently agreed to work with a commercialization partner if approval is granted in the US and Canada. Bausch & Lomb will be responsible for marketing the biosimilar in this country, marking the US eye care manufacturer’s first foray into the …
Biosimilarsrr.comAlvotech and STADA agree on strategic biosimilar ...
2019-11-06 · Alvotech and STADA enter into a strategic collaboration for seven biosimilar candidates in Europe; STADA will exclusively commercialise the products in all key European markets as well as selected markets outside of Europe; STADA CEO Peter Goldschmidt: “The agreement with Alvotech is one of the largest commercial biosimilar cooperations to date, …
Stada.comStrategic Biosimilar Development Partnership: STADA and ...
2019-05-31 · STADA and Xbrane have already entered into a co-development agreement for Xlucane, a Lucentis ® (ranibizumab) biosimilar, in July 2018. The agreement contains that both companies will equally contribute to development expenses and share profits from commercialization in a 50/50 split. STADA will hold the marketing authorizations and will be …
Stada.comSTADA strengthens oncology offering by launching ...
2021-03-30 · STADA has been engaged in bringing biosimilars to patients and healthcare professionals since founding the Bioceuticals Arzneimittel AG in 2000. Thereby, STADA contributes to the cost effectiveness of healthcare systems. The company has 13 years of market experience with its epoetin zeta treatment that has become one of STADA’s best-selling …
Stada.comStada to Invest $115 Million in Biosimilar Development
2018-08-06 · Stada, a biopharmaceutical company based in Germany, recently announced that it is increasing its presence in the biosimilar sphere by becoming the majority shareholder in Bioceuticals, a venture capital-funded organization created by Stada to carry out its biosimilar programs.. In addition to the shares Stada previously held in the company, it will be acquiring …
Centerforbiosimilars.comStada expands biosimilar range and in-licenses filgrastim ...
2013-10-29 · Apotex has licenced rights to its recently endorsed biosimilar filgrastim, Grastofil, to the German generics company, Stada Arzneimittel AG (Stada). Grastofil received a positive EMA CHMP endorsement on 25 July 2013 as a treatment of febrile neutropenia. The condition results in an abnormally low number of neutrophil granulocytes, a type of white blood cell that is …
Biosimilarz.wordpress.comGlobal Oncology Biosimilars Market (2022 to 2031 ...
2022-03-21 · The lack of awareness on biosimilars among primary care physicians (PCPs) and specialist limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, lack of detailed awareness on the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting …
Ca.finance.yahoo.comStrategic Biosimilar Development Partnership: STADA and ...
2019-05-31 · Bad Vilbel, May 31, 2019 – STADA Arzneimittel AG and Xbrane Biopharma AB have expanded their strategic biosimilar development partnership. This allows both companies to evaluate potential development and commercialization collaborations around Xbrane's Xcimzane and Xdivane preclinical biosimilars and additional biosimilars that fit both companies' …
Stada-apac.comStrategic Biosimilar Development Partnership: STADA and ...
Xbrane and STADA will focus on biosimilars to originator products with patent expiration 2025-2030 and have identified two programs in Xbrane´s pre-clinical biosimilar portfolio for potential future collaboration: Xcimzane (Certolizumab pegol (Cimzia®) biosimilar) and Xdivane (nivolumab (Opdivo®) biosimilar). Up until initiation of the products’ clinical trials STADA and …
Ipohub.ioStada Launches Bevacizumab Biosimilar In EU :: Generics ...
2021-03-31 · [email protected]. All fields are required. ... Subject: Stada Launches Bevacizumab Biosimilar In EU Add a personalized message to your email. Cancel. Send. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe. Sign In To Set a Search …
Generics.pharmaintelligence.informa.comStrategic Biosimilar Development Partnership: STADA and ...
STADA and Xbrane have already entered into a co-development agreement for Xlucane, a Lucentis® (ranibizumab) biosimilar in July 2018. The agreement contains that both companies will equally contribute to development expenses and share profits from commercialization in a 50/50 split. STADA will hold the marketing authorizations and will be responsible for sales and …
Xbrane.comBEGOñA GARCIA FEIJOO , Hospital & Biosimilars Rep. en ...
Verify the professional email of BEGOñA GARCIA FEIJOO , Hospital & Biosimilars Rep. en STADA, STADA. Email-verifier.io : the best email verifier in the world. Email-verifier.io. Back to homepage Email-Verifier.io is the BEST email verifier in the world. Test us for free! First ...
Directory.email-verifier.ioEpoetin zeta - Stada Arzneimittel/Pfizer - AdisInsight
2021-10-02 · Epoetin zeta - Stada Arzneimittel/Pfizer Alternative Names: 1-165-Erythropoietin (human clone B03XA01), glycoform zeta; Darbepoetin alfa biosimilar - Bioceuticals; Darbepoetin alfa biosimilar - Hospira; Darbepoetin alfa biosimilar - Stada; Darbepoetin biosimilar - Bioceuticals; Darbepoetin biosimilar - Hospira; Darbepoetin biosimilar - Stada; Epo-zeta; …
Adisinsight.springer.comStada Ranibizumab Deal Doesn’t Change Coherus’ Aspirations
2020-05-13 · With one foot already in oncology, biosimilars player Coherus is looking to make a splash in ophthalmology with ambitions to launch rivals to Lucentis and Eylea, as well as Avastin, in the US in the coming years. The US-based firm has acknowledged the competition it faces for biosimilars to Lucentis as Bausch Health picked up rights to Stada and Xbrane’s candidate …
Generics.pharmaintelligence.informa.com
Domains Expiration Date Updated
| Site | Provider | Expiration Date |
|---|---|---|
| historicloudontheatre.com | godaddy.com | -1 Years, -37 Days |
| techexperiencecentre.com | godaddy.com | -1 Years, -306 Days |
| musicasregistradas.com | godaddy.com | 4 Years, 180 Days |
| destinosguate.com | godaddy.com | -1 Years, -125 Days |
| mladeniotac.com | openprovider.com | -1 Years, -155 Days |
| fietstas.com | openprovider.com | -2 Years, -59 Days |
| halayalla.com | godaddy.com | -1 Years, -281 Days |
| minutewinner.com | godaddy.com | -2 Years, -14 Days |
| psyche.guru | cloudflare.com | 1 Year, 6 Days |
| goliadcad.org | domains.google.com | -1 Years, -225 Days |